The U.S. Food and Drug Administration (FDA) has recalled 300,000 cartons of Clonidine transdermal patches due to the use of an unapproved raw material in the manufacturing process. The products, made by Actavis Laboratories for Teva Pharmaceuticals, are three separate dosages in milligrams. The recall was initiated in March 2026 and classified as Class II by the FDA on April 13, 2026. The use of the unapproved ingredient is a violation of federal manufacturing standards. If you use these patches without consulting your doctor, it's not advisable to discontinue the drug.